Ozempic Babies: How GLP-1 Drugs Boost Fertility Unexpectedly

They are being called 'Ozempic babies' — unplanned pregnancies in women who were not expecting to conceive, often because years of irregular cycles or PCOS had made fertility feel out of reach. Reports began appearing in social media groups and fertility clinics around 2023, and by 2025 reproductive endocrinologists were seeing the pattern frequently enough to take it seriously: women on semaglutide and tirzepatide were getting pregnant — sometimes despite also being on hormonal contraception. The phenomenon is now well-documented enough that the American Society for Reproductive Medicine has issued updated guidance, and fertility specialists are increasingly fielding questions about it. Understanding why GLP-1 drugs appear to boost fertility, what the risks are during pregnancy, and what to do if you are trying to conceive or trying to avoid pregnancy while on these medications is now essential knowledge.

Why GLP-1 Drugs Appear to Restore Fertility

The fertility-boosting effect of GLP-1 drugs operates through several interconnected mechanisms, most of which flow from the drugs' primary action of producing meaningful weight loss. For women with obesity, even modest weight reduction — 5-10% of body weight — is sufficient to restore regular ovulatory cycles in many cases. Excess adipose tissue acts as an endocrine organ, producing estrogen from androgens via aromatase activity, which disrupts the hypothalamic-pituitary-ovarian (HPO) axis feedback loop and suppresses ovulation. Weight loss reduces this peripheral estrogen load, allowing normal cycle signaling to resume.

The effect is particularly pronounced in women with polycystic ovary syndrome (PCOS), the most common cause of anovulatory infertility. PCOS is strongly linked to insulin resistance, and GLP-1 receptor agonists improve insulin sensitivity through multiple pathways — reducing hepatic glucose output, improving muscle glucose uptake, and reducing fasting insulin levels. Lower insulin levels reduce ovarian androgen production (hyperandrogenism is a hallmark PCOS feature that disrupts follicle development), and improved insulin sensitivity also tends to reduce LH hypersecretion that drives follicular arrest. Multiple studies, including a 2024 randomized trial in Fertility and Sterility, demonstrated that semaglutide improved ovulation rates in women with PCOS more substantially than metformin alone over 24 weeks.

The Contraception Problem: Why Birth Control May Be Less Effective

A critical — and underappreciated — aspect of the Ozempic baby phenomenon is that GLP-1 drugs can reduce the effectiveness of oral contraceptives. The mechanism is gastric emptying delay. Oral contraceptive pills depend on reliable absorption from the small intestine, and GLP-1-driven changes in gut motility can alter the absorption kinetics of these drugs. Delayed gastric emptying means the pill may sit in the stomach longer and then transit the small intestine more rapidly once it does empty, potentially reducing peak plasma concentrations of ethinyl estradiol and progestin below the threshold needed for reliable ovulation suppression.

Several case reports and pharmacokinetic modeling studies support this concern. The FDA label for oral semaglutide (Rybelsus) already includes a warning about potential interactions with oral medications that depend on gastric pH and emptying rates. For injectable semaglutide, the effect is smaller but not zero. Reproductive endocrinologists are now advising patients on GLP-1 drugs who rely on oral contraceptives to use a backup method — particularly during the first year of GLP-1 use when motility changes are most pronounced, and after any dose increase. IUDs, implants, and barrier methods are not affected by GLP-1 gastric motility changes and provide more reliable protection.

Risks of Pregnancy While Taking a GLP-1 Drug

GLP-1 receptor agonists are classified as FDA Pregnancy Category D (risk cannot be ruled out) for semaglutide and tirzepatide, based on animal reproductive toxicity data showing increased rates of embryofetal abnormalities and fetal loss at clinically relevant doses. Human data is limited — most clinical trials excluded pregnant women — but case series from patients who became pregnant while on GLP-1 therapy have not yet shown a clear signal of congenital anomalies. The animal data is nevertheless sufficient to make drug discontinuation the standard recommendation upon confirmed pregnancy.

The recommended washout period before attempting conception is at least two months for semaglutide, based on its pharmacokinetic half-life of approximately one week and the time needed for full drug clearance. For tirzepatide, which has a similar half-life, a comparable washout period is recommended. The half-life of these drugs means that simply stopping the injection one week before conception is insufficient — meaningful plasma concentrations persist for four to eight weeks after the last dose. Women who discover they are pregnant while on GLP-1 therapy should discontinue immediately and contact their healthcare provider, but current data does not support elective termination based on GLP-1 exposure alone.

What Fertility Specialists Are Saying

The reproductive medicine community is navigating a rapidly changing landscape. Fertility specialists report that GLP-1 drugs are now among the most common reasons for unexpected resumption of ovulation in patients who had previously been anovulatory for years. Some reproductive endocrinologists are cautiously optimistic about the potential to use GLP-1 drugs as a pre-IVF weight optimization strategy in patients with obesity-related anovulatory infertility, followed by a two-month washout before egg retrieval. The 2025 American Society for Reproductive Medicine practice committee opinion noted that the weight loss and metabolic benefits of GLP-1 therapy may improve IVF outcomes, but recommended prospective studies before formal endorsement.

The PCOS angle is particularly compelling to specialists. PCOS is estimated to affect 8-13% of reproductive-age women globally and is the leading cause of female infertility. Current first-line treatments — metformin, clomiphene, letrozole — are partially effective, and many patients with PCOS and significant insulin resistance see incomplete responses. GLP-1 drugs address the insulin resistance and androgen excess that drive PCOS simultaneously, potentially offering a more targeted approach than existing therapies. Randomized trials specifically designed to evaluate GLP-1 drugs as fertility treatments in PCOS are now underway, with results expected in 2026-2027.

Men's Fertility on GLP-1 Drugs

The Ozempic baby conversation has focused primarily on women, but male fertility is also affected by GLP-1 therapy — largely in positive ways for men with obesity. Obesity is associated with lower testosterone levels, elevated estrogen (again via aromatase activity in fat tissue), and impaired sperm parameters including motility and morphology. Weight loss in obese men consistently improves testosterone levels and sperm quality, and GLP-1-driven weight loss appears to produce similar benefits. A 2024 prospective study in Andrology found that men with obesity on semaglutide for 24 weeks showed significant improvements in total testosterone, sperm concentration, and progressive motility compared to controls.

Concerns have been raised about whether direct GLP-1 receptor activation in testicular tissue could affect spermatogenesis — GLP-1 receptors are expressed in Leydig cells and the epididymis — but the currently available human data shows improvements in, not impairment of, sperm parameters. Men with obesity who are trying to conceive have reasonable grounds to discuss GLP-1 therapy with a reproductive urologist as part of a comprehensive fertility optimization plan. As with women, the safety data during the preconception and conception window is limited and warrants ongoing surveillance.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.